Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Chemotherapy & Immunotherapy
Chemotherapy for ovarian cancer
Chemotherapy for ovarian cancer uses cytotoxic drugs such as carboplatin and paclitaxel to destroy malignant cells or halt their growth. This guide covers first-line and maintenance protocols, how treatment is scheduled alongside surgery, what clinical evidence shows about recurrence, approximate costs in Turkey compared with the UK and Germany, expected side effects, travel logistics and how to choose an accredited medical oncology department.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Chemotherapy & Immunotherapy
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Chemotherapy for Ovarian Cancer
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Chemotherapy for ovarian cancer: what it is and how it works
Chemotherapy for ovarian cancer is a systemic cancer treatment using cytotoxic drugs to destroy rapidly dividing malignant cells throughout the body. In gynaecological oncology, it is central to treating epithelial ovarian, fallopian tube, and primary peritoneal cancers. Because ovarian cancer cells shed across the peritoneal cavity, surgery alone is rarely sufficient in advanced stages; systemic medicines circulate through the bloodstream to target visible tumours and microscopic deposits. Accredited cancer centres in Turkey provide international patients with diagnostic restaging, port placements, and outpatient infusion suites. For wider cancer care options, see our hub on oncology treatments in Turkey.
Cytotoxic drugs disrupt cellular division by damaging cancer cell DNA, preventing replication and prompting apoptosis. Treatment is scheduled in distinct settings: neoadjuvant chemotherapy before surgery to shrink extensive tumours; adjuvant chemotherapy after surgery to eliminate residual cells; and palliative-intent therapy to manage symptoms in recurrent cancer. This guide details drug protocols, clinical evidence, costs compared with the UK and Germany, side effects, and clinic standards.
Which drug regimens are used in ovarian cancer chemotherapy?
The standard first-line ovarian cancer chemotherapy regimens worldwide combine a platinum drug with a taxane, most commonly carboplatin and paclitaxel. Carboplatin cross-links cancer DNA to inhibit replication, while paclitaxel stabilises cellular microtubules, arresting division during mitosis. Given together intravenously every three weeks, this combination delivers potent synergistic cytotoxicity.
When paclitaxel causes marked neuropathy or allergic reactions, alternatives like pegylated liposomal doxorubicin or docetaxel may be substituted. For platinum-resistant recurrences, oncologists use non-platinum agents such as gemcitabine or topotecan. Selected centres also offer hyperthermic intraperitoneal chemotherapy (HIPEC) during surgery, bathing the abdominal cavity in heated drugs. Today, intravenous cytotoxic protocols are frequently followed by maintenance therapy; see our guide to chemotherapy in Turkey.
Does chemotherapy for ovarian cancer actually work?
Clinical trials and international guidelines from ESMO and NICE confirm that chemotherapy for ovarian cancer is highly effective as initial treatment. In newly diagnosed stage III and stage IV epithelial ovarian cancer, platinum-based adjuvant regimens achieve objective clinical response rates of 70% to 80%. When coupled with optimal surgical debulking—removing all visible tumours—chemotherapy significantly prolongs progression-free and overall survival.
However, clinical evidence also highlights real boundaries. Despite strong initial response, approximately 70% of advanced-stage patients experience recurrence within two to three years. Response rates in recurrent disease depend on the platinum-free interval: platinum-sensitive recurrences respond well to re-treatment, whereas platinum-resistant cases achieve response rates of roughly 15% to 25% with alternative drugs. A trustworthy medical oncology team will never promise a permanent cure for advanced cancer; they outline realistic expectations around remission length, symptom control, and quality of life.
Chemotherapy for ovarian cancer cost in Turkey compared with the UK, US and Germany
The figures below show approximate cost ranges for a standard six-cycle course of first-line intravenous chemotherapy (carboplatin and paclitaxel, including premedications and routine monitoring), not specific clinic quotes. Total chemotherapy for ovarian cancer price depends on drug brands, outpatient versus inpatient care, growth factor support, and restaging scans.
| Country | Approximate cost range |
|---|---|
| Turkey | €4,000 – €14,000 |
| United Kingdom | €12,000 – €35,000 |
| United States | €25,000 – €75,000 |
| Germany | €14,000 – €38,000 |
What changes the price: specific medication formulations (such as liposomal preparations), whether port-a-cath placement is needed, pre-treatment genetic tests (such as BRCA or HRD testing), and supportive injections. When choosing chemotherapy for ovarian cancer in Turkey, an international package typically includes pre-chemo laboratory panels, medical oncology consultations, day-case infusion suite fees, antiemetics, and bilingual coordinators. Additional scans and emergency care are invoiced separately; always request a written, itemised plan.
Chemotherapy, targeted therapy or immunotherapy: how do options compare?
Ovarian cancer treatment often combines cytotoxic chemotherapy with targeted or biological drugs based on tumour genetics.
| Method | Best suited to | Typical limits |
|---|---|---|
| Systemic chemotherapy (Carboplatin + Paclitaxel) | Frontline adjuvant treatment, neoadjuvant tumour shrinkage, and platinum-sensitive recurrences | Affects healthy dividing cells; causes temporary marrow suppression, fatigue, and neuropathy |
| Targeted therapy (PARP inhibitors / Bevacizumab) | Maintenance after chemotherapy response, especially with BRCA mutations or HRD positivity | Cannot replace frontline chemotherapy; depends on tumour genetics; high drug costs |
| Immunotherapy (Checkpoint inhibitors) | Selected recurrent cases with mismatch repair deficiency or high mutational burden | Limited benefit in standard epithelial ovarian cancer; requires strict biomarker qualification |
Systemic chemotherapy remains the core treatment to eliminate bulk disease. Once chemotherapy achieves a response, targeted drugs are often prescribed as oral maintenance; see our guide to targeted therapy. For specific recurrent tumour profiles, read our overview of immunotherapy.
Who is a candidate for ovarian cancer chemotherapy, and who is not?
Candidates for chemotherapy are women with diagnosed epithelial ovarian cancer (serous, clear cell, endometrioid, or mucinous), fallopian tube, or primary peritoneal cancer from stage IC through IV, as well as selected high-grade stage I presentations. Patients must demonstrate sufficient general health (typically an ECOG performance status of 0 to 2) alongside acceptable kidney, liver, and bone marrow function to process and clear cytotoxic drugs safely.
Chemotherapy is delayed or unsuitable for patients with severe active infections, unmanaged organ failure, or profound pre-existing bone marrow suppression. Severe pre-existing peripheral neuropathy may require drug substitutions to avoid disabling nerve injury. In elderly or frail patients, oncologists conduct geriatric assessments and may recommend lower weekly dosing schedules to reduce side effects while preserving therapeutic benefit.
What happens during a chemotherapy cycle step by step?
Treatment is delivered in cycles, typically once every three weeks (a 21-day cycle) across six total cycles. One or two days before infusion, blood tests check full blood counts, kidney values, and liver function. If neutrophil or platelet counts are too low, the oncologist delays treatment by several days to allow bone marrow recovery.
On treatment day, intravenous access is confirmed. Many patients have a subcutaneous port-a-cath placed in the chest wall, avoiding repeated vein punctures. Premedications including dexamethasone and antiemetics are administered to prevent allergic reactions and nausea. Paclitaxel is infused over three hours under regular nursing observation, followed by carboplatin over thirty to sixty minutes. The entire outpatient appointment takes five to six hours, after which the patient returns to their hotel with take-home medications.
Before and after chemotherapy: monitoring response and remission
Unlike aesthetic procedures where before and after changes are visual, cancer treatment progress is measured through tumour markers, clinical exams, and restaging scans. Before starting chemotherapy, baseline CT scans of the chest, abdomen, and pelvis and a CA-125 blood test establish the tumour's initial size and metabolic activity.
During treatment, an interim scan after cycle three checks whether tumours are shrinking. After completing all six cycles, a definitive restaging CT or PET-CT scan and CA-125 test evaluate response under RECIST guidelines. A complete response means all measurable tumour deposits have disappeared and CA-125 has normalised below 35 U/mL. A partial response indicates at least a 30% reduction in tumour dimensions. An ethical oncology team will explain that a clean scan indicates no detectable active disease, not proof that microscopic cells cannot return.
Chemotherapy for ovarian cancer recovery and managing side effects
Chemotherapy for ovarian cancer recovery follows a cyclical pattern across the three-week interval. Days one to three bring mild fatigue and nausea, generally well controlled by modern antiemetics. Days four to seven frequently involve muscle and joint aches from paclitaxel. Days ten to fourteen mark the white blood cell nadir, when infection risk is highest and energy dips. Energy levels rebound through days fifteen to twenty-one, preparing the body for the next cycle.
Patients travelling for chemotherapy for ovarian cancer Turkey typically stay in the country for four to seven days per cycle for blood tests, infusion, and immediate monitoring. With oncological clearance, patients can fly home for the remaining two weeks, returning for their next infusion. Support strategies include cold capping to reduce hair loss, cooling mitts to protect peripheral nerves, and staying hydrated while flying to minimise clot risks.
Risks and potential complications of treatment
Chemotherapy carries documented pharmacological risks that require vigilant monitoring. The primary acute risk is neutropenia. Health authorities including the NHS, ASCO, and ESMO warn that a fever above 38°C or sudden shivering during chemotherapy is a medical emergency requiring urgent hospital evaluation and intravenous antibiotics.
Other recognized complications include sensory peripheral neuropathy (numbness or tingling in fingers and toes), anaemia causing fatigue, thrombocytopenia increasing bleeding risks, and temporary hair loss. Hypersensitivity reactions can occur during taxane or platinum infusions, requiring immediate medical intervention. Long-term risks include rare kidney impairment, mild hearing changes, and temporary cognitive fatigue. Reputable cancer centres manage these risks through routine blood monitoring, dose modifications, and supportive growth factors.
How to choose an oncology centre in Turkey and questions to ask
Selecting a cancer centre abroad requires careful verification. Look for hospitals accredited by Joint Commission International (JCI) or ISO, ensuring strict pharmacy compounding and safety standards. Confirm your care plan is reviewed by a formal Multidisciplinary Tumour Board, where medical oncologists, gynaecological surgeons, radiologists, and pathologists collaborate. Red flags include clinics quoting fixed prices without reviewing pathology slides or imaging, facilities without on-site intensive care, pressure to book immediately, or promises of a permanent cure.
Learn how medical travel is coordinated by reading how our process works, or submit your medical records through our free quote page for a multidisciplinary review. Essential questions to ask the clinic include:
- Does a gynaecological tumour board review my biopsy and imaging before setting my protocol?
- What exact drug combination, dosing, and schedule do you recommend for my stage?
- Will a named medical oncologist supervise each infusion?
- Is there an on-site emergency department and intensive care unit available 24/7?
- Can you place a port-a-cath before my first treatment?
- What supportive measures, such as cold capping, are available for side effects?
- What medical reports and blood results will I receive to give my home doctor?
Conditions treated with Chemotherapy for Ovarian Cancer
Hospitals with Oncology in Turkey
Frequently asked questions
Chemotherapy for ovarian cancer uses cytotoxic medicines, most commonly carboplatin combined with paclitaxel, to kill rapidly dividing cancer cells or arrest their multiplication. It is delivered intravenously or directly into the abdomen, either before debulking surgery to shrink tumours or after surgery to clear microscopic disease.
Yes. Clinical guidelines from ESMO and NICE confirm that platinum-based chemotherapy achieves initial response in over 70% to 80% of newly diagnosed advanced epithelial ovarian cancers. While it frequently induces clinical remission, advanced stages carry a significant risk of recurrence, which is why oncologists closely monitor tumour markers and imaging.
A complete six-cycle course of chemotherapy for ovarian cancer in Turkey typically ranges from €4,000 to €14,000, compared with €12,000 to €35,000 in the UK. Exact pricing depends on the specific drug regimen, supportive medications, hospital stay, and diagnostic monitoring, which are detailed in a personalised written quote.
Unlike cosmetic surgery, before and after assessments evaluate disease response through diagnostic testing. Before treatment, baseline CT scans and CA-125 blood tests establish tumour burden. After cycles, repeat imaging and blood markers show whether tumours have shrunk, stabilised, or disappeared, indicating partial or complete radiological and biochemical remission.
Chemotherapy is usually given in cycles spaced three weeks apart. Acute fatigue and nausea typically peak within the first three to five days after infusion. Blood cell counts drop around day ten to fourteen before recovering by day twenty-one, allowing patients to regain energy before their next planned cycle.
The intravenous infusion itself causes minimal physical discomfort, though patients may feel a slight pinch during needle insertion or port access. Mild stinging can occur if medication irritates a peripheral vein. Muscle aches, joint stiffness, and nausea can develop in the days following infusion and are managed with prescribed medications.
Remission duration depends on cancer stage, tumour genetics like BRCA status, and surgical clearance. Early-stage disease often achieves long-term remission or cure. Advanced disease may remain in remission for months or years, after which maintenance therapy or second-line chemotherapy may be recommended if CA-125 levels or scans indicate recurrence.
Key risks include neutropenia, which lowers infection resistance, anaemia, peripheral neuropathy causing numbness or tingling in hands and feet, allergic reactions during taxane infusion, and temporary hair loss. Hospital oncology teams monitor blood counts weekly and adjust dosages or provide growth factor support to mitigate severe complications.
Chemotherapy attacks all rapidly multiplying cells and remains the primary frontline treatment. Targeted therapies, such as PARP inhibitors or anti-angiogenic drugs, interfere with specific molecular pathways or genetic mutations like BRCA. They are frequently used as maintenance following successful chemotherapy rather than replacing cytotoxic treatment entirely.
International patients usually stay in Turkey for four to seven days per cycle. This allows time for pre-treatment blood tests, specialist consultation, the day-case infusion, and medical observation during the immediate post-infusion window before flying home, returning every three weeks for subsequent cycles.
Patient stories